Nasus Pharma H1 FY26 net loss widens to $5.94 million
NSRX•H1 FY26 results and cash position
- Nasus Pharma posted a net loss of USD 5.9 million for the six months ended June 30, 2026, widening from USD 1.3 million.
- R&D expense rose to USD 2.6 million from USD 0.3 million, driven by spending tied to NS002 development.
- G&A costs climbed to USD 3.4 million from USD 0.5 million, mainly due to expenses of becoming a public company.
- Cash, cash equivalents and short-term deposits increased to USD 11.9 million from USD 4.3 million, following a USD 15 million private placement.
- Nasus named Brendan P. O’Grady CEO; NS002 pivotal study remains slated for Q4 2026, with topline data expected in Q1 2027.
